Skip to content
Dosage GuideResearch Reference

Tesamorelin Dosage

Research-based dosing protocols, timing guidance, and reconstitution reference for Tesamorelin. All information is for educational purposes only.

Quick Answer

Tesamorelin is typically administered at 2 mg daily via subcutaneous injection. It is the only FDA-approved GHRH analog and is indicated for the reduction of excess abdominal fat in HIV-infected patients. Research protocols vary in duration, but most clinical trials use a 6–12 month regimen.

→ Tesamorelin Benefits→ Tesamorelin Side Effects→ Full Tesamorelin Profile
Table of Contents

Standard Dosage Range

Research dosing range: 2 mg daily

Educational reference only

These dosage ranges are derived from preclinical research and community protocols. No human clinical dose-ranging trials have established therapeutic doses for most research peptides. Always consult a qualified healthcare provider before starting any peptide protocol.

Dosage by Use Case

HIV-Associated Lipodystrophy

2 mg1× daily
Duration

6–12 months

FDA-approved indication. Subcutaneous injection. Dosage based on clinical trials demonstrating efficacy in reducing abdominal fat in HIV-infected individuals.

NAFLD (Non-Alcoholic Fatty Liver Disease) - Research

2 mg1× daily
Duration

6 months

Based on emerging research showing potential benefits for reducing hepatic fat. Subcutaneous injection. Requires medical supervision.

Cognitive Enhancement (Research)

2 mg1× daily
Duration

12 months

Based on preliminary studies suggesting improvements in cognitive function. Subcutaneous injection. Requires medical supervision.

Timing & Frequency

Tesamorelin is administered via subcutaneous injection, ideally at the same time each day. Some individuals prefer morning administration, while others find evening administration more suitable. Consistency is key to maintaining stable growth hormone levels.

Cycle Guidance

Clinical trials and FDA guidelines recommend a treatment duration of 6–12 months. Longer durations may be considered under medical supervision, weighing potential benefits against the risk of side effects. Cycling is generally not required, but a break can be considered after 12 months.

Reconstitution Reference

Quick reference for reconstituting Tesamorelin. For custom vial sizes and concentrations, use the Reconstitution Calculator.

Common Vial SizeTypically 1 mg or 2 mg per vial
BAC Water Volume1 mL bacteriostatic water for 1 mg/mL or 2 mg/mL concentration, respectively
Concentration & DrawAt 2 mg/mL: 2 mg = 1 mL (100 units on a 100-unit insulin syringe). At 1mg/mL: 2mg = 2mL (200 units on a 100-unit insulin syringe)
StorageRefrigerate at 2–8°C after reconstitution. Keep lyophilized powder at room temperature or refrigerated.
StabilityReconstituted solution stable up to 14 days refrigerated. Lyophilized powder stable 12–24 months per manufacturer specifications.
Use the Reconstitution Calculator → for precise injection volumes based on your exact vial size, water volume, and desired dose.

Frequently Asked Questions

What is the standard tesamorelin dosage for HIV-associated lipodystrophy?
The FDA-approved dosage for treating HIV-associated lipodystrophy is 2 mg daily, administered via subcutaneous injection. This dosage is based on clinical trials demonstrating efficacy in reducing excess abdominal fat in this patient population.
How long does it take to see results with tesamorelin?
Significant reductions in visceral abdominal fat are typically observed after 6 months of consistent daily administration of 2 mg tesamorelin. Improvements in other parameters, such as liver fat and cognitive function, may take longer to manifest.
What is the best time of day to inject tesamorelin?
The optimal time of day for tesamorelin injection varies among individuals. Some prefer morning administration, while others find evening administration more suitable. Consistency is key. Choose a time that fits your routine and stick with it.

Last updated: 2026-02-19